港股異動 | 藥明巨諾-B(2126.HK)首日掛盤漲近6% 每中籤一手浮盈700港元
格隆匯11月3日丨藥明巨諾-B(2126.HK)首日掛盤開報24.35港元,較招股價23.8港元高2.3%,成交額2.9億港元,盤初漲幅擴大至近6%,報25.2港元,總市值95億港元;每中籤一手浮盈700港元。藥明巨諾是中國領先的臨牀及臨牀前階段細胞治療公司,也是國內首個獲得以CD19為靶點的CAR-T細胞治療產品IND臨牀批件的企業。此次上市擬全球發售9769.2萬股,其中香港發售4884.6萬股,國際發售4884.6萬股,每手500股,中籤率5%,香港公開發售獲449.42倍認購,淨籌21.967億港元。在過往融資記錄中,公司獲得淡馬錫、紅杉等知名投資機構的青睞。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.